A national platform trial that every ctDNA-positive patient can join
Blood tests can now find leftover cancer months before scans, but most patients who test positive have nothing to enrol in. One standing trial per country would fix that.
MRD-guided intervention has proved feasible in bladder cancer and colorectal cancer, but each trial rebuilds the same infrastructure: assay contracts, testing schedules, referral pathways and consent. A standing national platform — one master protocol, shared control arm, rolling arms contributed by any sponsor, registry-based follow-up — converts a scattered set of underpowered studies into a permanent engine for the MRD setting.
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
Pages like this
not linked directly; found by shared links- IdeaFormally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials
Shares DYNAMIC, IMvigor011, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), Dormant cells and minimal residual disease.
- IdeaOne standing umbrella trial for all rare cancers in a country
Shares AI trial matching & clinical decision support, Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Cancer Research UK.
- IdeaA national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Shares DYNAMIC, IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
- IdeaA dedicated clinic for people whose blood test says the cancer is back
Shares AI trial matching & clinical decision support, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeactDNA-guided adjuvant therapy as the default in stage II-III colon cancer
Shares DYNAMIC, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
- IdeactDNA-guided adjuvant therapy in stage II-III melanoma
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaStrip the platelet coat off travelling tumour cells in ctDNA-positive patients
Shares DYNAMIC, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- IdeaUse tumour DNA in blood to decide when to pause treatment in metastatic cancer
Shares DYNAMIC, IMvigor011, MRD / molecular residual disease testing, Trial design, endpoints and cost.